Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center

home / authors / ola-landgren-md-phd-sylvester-comprehensive-cancer-center

Articles

C. Ola Landgren, MD, PhD

Dr Landgren on the Utility of MRD as an End Point in Multiple Myeloma Trials

Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center
May 29th 2024

C. Ola Landgren, MD, PhD, discusses the utility of minimal residual disease as an end point in clinical trials for the treatment of multiple myeloma.

Read More

Third and Subsequent Line Options for Multiple Myeloma

Third and Subsequent Line Options for Multiple Myeloma

Ajai Chari, MD, Mount Sinai Hospital;Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center;Saad Z. Usmani, MD, FACP, Levine Cancer Institute;Meletios A. Dimopoulos, MD, The National and Kapodistrian University of Athens
January 29th 2021

Read More

Updates in Relapsed/Refractory Myeloma

Updates in Relapsed/Refractory Myeloma

Ajai Chari, MD, Mount Sinai Hospital;Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center;Saad Z. Usmani, MD, FACP, Levine Cancer Institute;Meletios A. Dimopoulos, MD, The National and Kapodistrian University of Athens
January 29th 2021

Read More

Updates in Multiple Myeloma in the Frontline Setting

Updates in Multiple Myeloma in the Frontline Setting

Ajai Chari, MD, Mount Sinai Hospital;Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center;Saad Z. Usmani, MD, FACP, Levine Cancer Institute;Meletios A. Dimopoulos, MD, The National and Kapodistrian University of Athens
January 29th 2021

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need